Notably, in A549 tumor-bearing BALB/c nude mice, intravenous administration of Ctx-CMA surpassed conventional cetuximab therapy, exhibiting both enhanced tumor growth suppression and a significant reduction in EGFR protein levels compared to control groups (IgG-CMA and Ctx alone). Here, EGFR is linked to neoplasm.